BACKGROUND: The transfusion of @entity1261 -primed granulocytes (GTX) might represent an important treatment option for @entity1398 -related infections unresponsive to conventional antimicrobial therapies and to recombinant hematopoietic growth factors. However, few studies to date have identified the factors that can predict clinical outcome and the @entity1 populations who are likely to benefit most from GTX. The primary endpoint of the present retrospective study was to evaluate the efficacy of GTX in 22 @entity1 with @entity1583 who developed @entity1398 -related @entity2348 that were unresponsive to appropriate antimicrobial therapies. METHODS: Peripheral blood granulocytes were collected by continuous-flow leukapheresis from HLA-identical siblings after priming with @entity1261 . The response to GTX was classified as 'favorable' if clinical symptoms and signs of @entity281 resolved or 'unfavorable' if clinical symptoms and signs of @entity281 were unchanged or worsened. Control of @entity281 at Day 30 after the enrollment in the GTX program was considered as the outcome variable in multiple regression analysis. RESULTS: Two @entity1 died of @entity281 before receiving the granulocyte concentrates. @entity2348 (monomicrobial or mixed @entity2259 ) were documented in 11 @entity1 , whereas @entity364 ( @entity12045 or focal @entity364 ) were diagnosed in seven @entity1 . In two @entity1 , no infecting agent could be isolated ( @entity922 ). Control of @entity281 at Day 30 after the first GTX was achieved in 10 of 20 assemble @entity1 . Overall, 54% of @entity1 with @entity2348 had a favorable response, compared with 57% of @entity1 with @entity364 . No differences in terms of survival were found when comparing @entity1 with bacterial and those with @entity364 at a median follow-up 90 days from the first GTX. In univariate analysis, disease status before GTX, e.g., complete or partial remission, and spontaneous recovery of the neutrophil count were significantly associated with control of @entity281 . when multivariate regression models were formed, the recovery 0.5 x 10 (9)/L PMN was the only parameter that significantly and independently correlated with a favorable response to GTX. DISCUSSION: GTX can be used to successfully treat bacterial as well as @entity364 in severely @entity1398 @entity1 when administered early after the onset of @entity1398 in @entity1 with remission of the underlying disease and who are likely to recover marrow function.

Efficacy of granulocyte transfusions for XXXX -related infections: retrospective analysis of predictive factors.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'G-CSf'] @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infections', 'bacterial and fungal infections', 'Bacterial infections'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'neutropenic', 'febrile neutropenia'] @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies'] @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremias'] @entity12045 :: ('MESH:D016469', 'Disease') :: ['fungemia'] @entity922 :: ('MESH:D013568', 'Disease') :: ['clinical infection']
@entity1398 :: (MESH:D009503,Disease) :: ['neutropenia']
